Loading...
Docoh

Precipio (PRPO)

Filed: 15 Sep 11, 8:00pm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):
September 13, 2011
 
 
 TRANSGENOMIC, INC. 
 (Exact name of registrant as specified in its charter) 
     
Delaware 000-30975 911789357
(State of Incorporation) (Commission File Number) (IRS Employer Identification  Number)
     
12325 Emmet Street, Omaha, Nebraska 68164
(Address of principal executive offices) (Zip Code)
     
 (402) 452-5400 
 (Registrant’s telephone number, including area code) 
     
 Not applicable 
 (Former name or former address, if changed since last report) 

 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 

 
 
Item 7.01 Regulation FD Disclosure.
 
On September 12 and 13, 2011 registrant participated in an investment community meeting in New York, New York.  In connection with this meeting registrant gave a presentation to investors on September 13, 2011.  A copy of the presentation used in such meeting is attached as Exhibit 99.1 hereto.

The information under this Item 7.01 and in Exhibit 99.1 hereto is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section.  The information under this Item 7.01 and Exhibit 99.1 hereto shall not be deemed incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, unless otherwise expressly indicated in such a registration statement or other document.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits

 Exhibit No.Description
 99.1 Investor presentation slides
 
 
 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
   
Dated: September 16, 2011
TRANSGENOMIC, INC. 
   
    
 By:/s/ Brett L. Frevert 
  Brett L. Frevert 
  Chief Financial Officer